NCT00786097

CompletedPhase 3

Dermacyd PH_DETINLYN (Lactic Acid) Tangerine Mix - Compatibi...

Sanofi Source

Compare

Other study identifiers

Sponsor study identifier

LACAC_L_04305

Study Type

interventional

Actual enrollment (reported)

53

Locations

1 country

Sites

1

Timeline

Study Start

July 2008

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

September 2008

Actual (reported)

Study Completion

September 2008

Actual (reported)

Brief Summary

The purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd PHDETINLYN Tangerine Mix.None.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 53 participants
Study completion date: September 2008
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
July 2008
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
September 2008
Actual (reported)
Study Completion
September 2008
Actual (reported)
First Submitted
November 4, 2008
Actual (reported)
First Posted
November 5, 2008
Actual (reported)

Last Updated: August 25, 2009
Status Verified: August 2009
Last Update Submitted: August 21, 2009

Conditions

Hygiene

Outcome Measures

Primary Outcomes (1)

The absence of primary and accumulated dermical irritability and dermical sensitivity will be evaluated using International Contact Dermatitis Research Group (ICDRG) scale.
Throughout the study

Study Arms (1)

1

EXPERIMENTAL

Dermacyd PH\_DETINLYN (Lactic Acid)

Drug: Dermacyd PH_DETINLYN (Lactic Acid)

Interventions

Dermacyd PH_DETINLYN (Lactic Acid)Drug

1

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 60 Years

Sexfemale

Healthy VolunteersYes

Age GroupsAdult (18-64)

You may qualify if:

Phototype Skin I,II, III e IV
Integral skin test in the region;

Sponsors & Collaborators

Sanofi
Industrylead

Study Sites (1)

Sanofi-Aventis Administrative Office

São Paulo, Brazil

MeSH Terms

Interventions

Lactic Acid

Intervention Hierarchy (Ancestors)

LactatesHydroxy AcidsCarboxylic AcidsOrganic Chemicals

Study Officials

Jaderson Lima
Sanofi
STUDY DIRECTOR

Enrollment

53 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 3
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: SUPPORTIVE CARE
Intervention Model: SINGLE GROUP
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

November 4, 2008

First Posted

November 5, 2008

Study Start

July 2008

Date type not reported

This date has not been verified as actual or estimated.

NCT00933907

Dermacyd PH_DESILSTY_FR (Lactic Acid) - Compatibility - Stay on Frutal

Phase 3Completed

NCT00784121

Dermacyd Breeze (Lactic Acid) Pocket BR - Compatibility

Phase 3Completed

NCT00783861

Dermacyd Femina (Lactic Acid) Pocket BR - Compatibility

Phase 3Completed

NCT00785642

Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Safety.

Phase 3Completed

NCT00933504

Dermacyd Silver Floral (Lactic Acid) - Compatibility - Stay on Floral

Phase 3Completed

NCT00783666

Dermacyd PH_DETINBACK Tangerine Mix (Lactic Acid) - Photo Evaluation

Phase 3Completed

Willingness in following the study procedures and to be present in the clinic at the days and scheduled time for medical evaluations and for application of occlusion;

Lactation or gestation

Use of Antiinflammatory and/or immunossupression drugs

Personnel history of atopy;

History of sensitivity or irritation for topic products;

Active cutaneous disease;

Use of new drugs or cosmetics during the study

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contact the study team to confirm eligibility.

Primary Completion

September 2008

Actual (reported)

Study Completion

September 2008

Actual (reported)

Last Updated

August 25, 2009

Record last verified: 2009-08

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00786097
Data provider: ClinicalTrials.gov
Source updated: 2009-08-25
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:26:08 UTC

Locations

BR(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

1

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations